Baycox Sheep, 50 mg/ml oral suspension.

Land: Irland

Språk: engelska

Källa: HPRA (Health Products Regulatory Authority)

Aktiva substanser:

Toltrazuril

Tillgänglig från:

Bayer Limited

ATC-kod:

QP51AJ01

INN (International namn):

Toltrazuril

Dos:

50 milligram(s)/millilitre

Läkemedelsform:

Oral suspension

Receptbelagda typ:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapeutisk grupp:

Sheep

Terapiområde:

toltrazuril

Terapeutiska indikationer:

Coccidiostats

Bemyndigande status:

Authorised

Tillstånd datum:

2009-01-30

Produktens egenskaper

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baycox Sheep, 50 mg/ml oral suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
White or yellowish oral suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
For Sheep (lambs).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the prevention of clinical signs of coccidiosis and reduction of
coccidia shedding in lambs on farms with a
confirmed history of coccidiosis caused by_ Eimeria crandallis_ and_
Eimeria ovinoidalis_.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As with any antiparasiticide frequent and repeated use of
antiprotozoals from the same class may lead to the
development of resistance.
It is recommended to treat all lambs in a pen.
Hygienic measures may reduce the risk of ovine coccidiosis. It is
therefore, recommended to improve concomitantly
the hygienic conditions in the concerned facility, particularly
dryness and cleanliness.
To obtain maximum benefit, animals should be treated before the
expected onset of clinical signs, i.e. in the prepatent
period.
ACTIVE SUBSTANCE:
1 ml contains:
Toltrazuril
50.0 mg
EXCIPIENTS:
Sodium benzoate (E211)
2.1 mg
Sodium propionate (E281)
2.1 mg
For a full list of excipients, see section 6.1
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_7_
_/_
_0_
_9_
_/_
_2_
_0_
_1_
_2_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_1_
_0_
_9_
_3_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUT